Financial Year 2010-2011 Annual Report Half Year Report   Financial Year 2009-2010 Annual Report Half Year Report   Financial Year 2008-2009 Annual Report Half Year Report

 

Van Leeuwenhoeck Institute initiates coverage on BioDiem (ASX: BDM)

BioDiem Licenses LAIV Technology

Appendix 4C - Quarterly Update

New issue announcement

BioDiem acquires Savine Therapeutics Pty Ltd

Investor Presentation

Results of Meeting

AGM Presentation

AGM Chairman's Address

BioPartnering Europe Presentation

Investor Presentation

AGM - Notice of Meeting

Annual Report

Full Year Results Commentary

Appendix 4E

Licenses LAIV to Serum Institute of India

Replaces Nobilon as Licensor to WHO

Regains LAIV technology rights

Half Year Results

US$0.25m Royalties Received on Nasovac Sales

US & China Patents Granted for BDM-I

Merck/Schering-Plough Update

Results of Annual General Meeting

AGM Presentations

Chairman's Address to Shareholders

Placement of $1m of Rights Issue Shortfall

Appointment of Projects Manager

FDA Grants Orphan Drug Status to BDM-E

LAIV Featured at International Conference

Annual Report

Financial Results

LAIV Launched in India